Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis

Magnetic Resonance Cholangiopancreatography Severity Predicts Disease Outcomes in Pediatric Primary Sclerosing Cholangitis: A Reliability and Validity Study

“…The largest and most rigorous validation study of MRCP for predicting outcomes in PSC was recently undertaken by Lemoinne et al In contrast to the above studies, which examined the score validated by Ponsioen et al, Lemoinne et al validated the Anali score. The Anali score was developed by Ruiz et al in 2014 .…”

“…Two scores were derived: one without gadolinium (including intrahepatic dilatation, liver dysmorphy, and portal hypertension) and one with gadolinium (dysmorphy and parenchymal enhancement heterogeneity). In the retrospective validation study by Lemoinne et al, which included two 119‐patient validation cohorts (internal and external), the Anali scores without and with gadolinium were found to have c‐statistics of 0.89 (95% CI, 0.84‐0.95) and 0.75 (95% CI, 0.64‐0.87) for predicting survival without LT or cirrhosis decompensation. The score without gadolinium performed best.…”

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

“…Annali score (MRCP) MRC findings of intrahepatic bile duct dilatation, dysmorphy (lobar atrophy, lobular surface changes, or an abnormal caudate to right lobe volume ratio) and portal hypertension Annali score without gadolinium was associated with clinical outcome in a single center study, then validated in two independent panels in a large, international, multicentre study [203,204] Major weight on late changes related to cirrhosis Dynamic changes are likely to be slow Invasive J Gastroenterol (2020) 55:588-614 607 laboratory values, and based on logistic regressions or machine-learning methodology, have been suggested to serve prognostic purposes yet frequently include ALP [187,188]. The prognostic scores may turn out to represent useful surrogate endpoints, although the most widely used clinical model, the revised Mayo risk score, demonstrated limited utility in early stage disease and failed to predict the negative outcome of the high-dose UDCA trial.…”

Issue Highlights

“…In a recent study in Clinical Gastoenterology and Hepatology, simple magnetic resonance scores associated with outcomes in PSC. 10 Liver stiffness (LS) is a measure of hepatic fibrosis which may represent a meaningful surrogate endpoint for PSC and can be measured through magnetic resonance elastography (MRE) with the latter being able to sample a larger volume of the liver and have potential for combining with an MRCP. In this issue, Eaton et al 11 described 204 patients with PSC who were followed for a median of 4 years and had 2 MRE measurements, a median of 1.10 years apart.…”